Company Overview and News

 
Greenyard Foods reports H1 2016/17

2016-11-22 northern-observer
Fresh and processed food company Greenyard Foods reported sales in the first half of its 2016/17 financial year were up 8.6% at €2,146.1 million compared to €1,975.6 million in the same period of last year.

 
Mahindra Agri Solutions invests in startup MeraKisan

2016-09-28 moneycontrol
He said Mahindra Univeg is a 60:40 joint venture between Mahindra Group's Mahindra Agri Solutions and Belgium-based Univeg (Greenyard Foods).

 
Mahindra Univeg to sell fruits, vegetables online

2016-09-28 thehindubusinessline
Mahindra Agri Solutions, a part of Mahindra & Mahindra Group, has formed a joint venture with Belgium-based Univeg (Greenyard Foods) to source fruits and vegetables directly from farmers and retail them on e-commerce platform www.shopping.merakisan.com.

 
Greenyard opens expanded Polish plant

2016-09-08 northern-observer
Fresh and processed food company Greenyard Foods announced it had opened its expanded plant in Lipno, Poland, which now encompasses 22,000 sqm.

 
Greenyard Foods sells fruit coop stake

2016-09-02 northern-observer
Fresh and processed food company Greenyard Foods announced it was divesting its equity stake in Belgium fruit producers cooperative Veiling Haspengouw.

 
Greenyard Foods update Q1 2016/17

2016-08-30 northern-observer
Fresh and processed food company Greenyard Foods reported group sales were up 8.4% year on year in the first quarter of the financial year 2016/17 at €1,119.7 million, of which 5.9% was internal growth.

 
Greenyard Foods joint venture with UK fruit producer

2016-07-28 northern-observer
Fresh and processed food company Greenyard Foods announced its Fresh division had concluded a joint venture with UK based Bardsley Farms Ltd in which it will take a minority stake.

 
Nomad Foods: Don't Discount Stéfan Descheemaeker And Martin Franklin

2016-06-20 seekingalpha
Shares of Nomad Foods have been decimated as excitement over the acquisition-driven bull thesis subsided and fears of execution risks took over.

 
Nomad Foods: Don't Discount Stéfan Descheemaeker & Martin Franklin

2016-06-20 seekingalpha
Shares of Nomad Foods have been decimated as excitement over the acquisition-driven bull thesis subsided and fears of execution risks took over.

 
Greenyard Foods stable 2015/16

2016-06-07 northern-observer
Fresh and processed food company Greenyard Foods reported sales for the financial year ending 31 March 2016 were stable at €3,967.3 million compared to €4,012.2 for the whole group in the previous year.

 
Greenyard completes Lutèce acuisition

2016-04-07 northern-observer
Fresh and processed food company Greenyard Foods reported it had completed the acquisition of Dutch based mushroom processor Lutèce.

 
Greenyard Foods reports 2015 Univeg results

2016-02-29 northern-observer
Food company Greenyard Foods reported results for 2015 for its recently merged fresh food business Univeg showing sales were down 2.3% at €751.9 million in the last 3 months of 2015 compared to the same period in 2014 but were up for the 12 months.

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...